» Articles » PMID: 22231702

IL-21 Receptor is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J Mice

Abstract

MRL/MpJ-Fas(lpr/lpr)/J (MRL(lpr)) mice develop lupus-like disease manifestations in an IL-21-dependent manner. IL-21 is a pleiotropic cytokine that can influence the activation, differentiation, and expansion of B and T cell effector subsets. Notably, autoreactive CD4(+) T and B cells spontaneously accumulate in MRL(lpr) mice and mediate disease pathogenesis. We sought to identify the particular lymphocyte effector subsets regulated by IL-21 in the context of systemic autoimmunity and, thus, generated MRL(lpr) mice deficient in IL-21R (MRL(lpr).IL-21R(-/-)). Lymphadenopathy and splenomegaly, which are characteristic traits of the MRL(lpr) model were significantly reduced in the absence of IL-21R, suggesting that immune activation was likewise decreased. Indeed, spontaneous germinal center formation and plasma cell accumulation were absent in IL-21R-deficient MRL(lpr) mice. Correspondingly, we observed a significant reduction in autoantibody titers. Activated CD4(+) CD44(+) CD62L(lo) T cells also failed to accumulate, and CD4(+) Th cell differentiation was impaired, as evidenced by a significant reduction in CD4(+) T cells that produced the pronephritogenic cytokine IFN-γ. T extrafollicular helper cells are a recently described subset of activated CD4(+) T cells that function as the primary inducers of autoantibody production in MRL(lpr) mice. Importantly, we demonstrated that T extrafollicular helper cells are dependent on IL-21R for their generation. Together, our data highlighted the novel observation that IL-21 is a critical regulator of multiple pathogenic B and T cell effector subsets in MRL(lpr) mice.

Citing Articles

IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials.

Koh C, Kim B, Kang C, Chung Y, Seo H Immune Netw. 2024; 24(1):e2.

PMID: 38455465 PMC: 10917578. DOI: 10.4110/in.2024.24.e2.


AP-1-independent NFAT signaling maintains follicular T cell function in infection and autoimmunity.

Seth A, Yokokura Y, Choi J, Shyer J, Vidyarthi A, Craft J J Exp Med. 2023; 220(5).

PMID: 36820828 PMC: 9998660. DOI: 10.1084/jem.20211110.


Composition and regulation of the immune microenvironment of salivary gland in Sjögren's syndrome.

Tan Z, Wang L, Li X Front Immunol. 2022; 13:967304.

PMID: 36177010 PMC: 9513852. DOI: 10.3389/fimmu.2022.967304.


CD8 follicular T cells localize throughout the follicle during germinal center reactions and maintain cytolytic and helper properties.

Valentine K, Mullins G, Davalos O, Seow L, Hoyer K J Autoimmun. 2021; 123:102690.

PMID: 34274825 PMC: 9374523. DOI: 10.1016/j.jaut.2021.102690.


The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.

Papillion A, Ballesteros-Tato A Front Immunol. 2021; 12:667342.

PMID: 33986755 PMC: 8112607. DOI: 10.3389/fimmu.2021.667342.


References
1.
Wong C, Lit L, Shan Tam L, Li E, Wong P, Kei Lam C . Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127(3):385-93. DOI: 10.1016/j.clim.2008.01.019. View

2.
Tieng A, Peeva E . B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum. 2008; 38(3):218-27. DOI: 10.1016/j.semarthrit.2007.11.003. View

3.
Chen X, Yu Y, Deng H, Sun J, Dai Z, Wu Y . Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol. 2010; 30(2):221-5. DOI: 10.1007/s10875-009-9365-x. View

4.
Budd R, Schumacher J, Winslow G, Mosmann T . Elevated production of interferon-gamma and interleukin 4 by mature T cells from autoimmune lpr mice correlates with Pgp-1 (CD44) expression. Eur J Immunol. 1991; 21(4):1081-4. DOI: 10.1002/eji.1830210435. View

5.
Webb R, Merrill J, Kelly J, Sestak A, Kaufman K, Langefeld C . A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 2009; 60(8):2402-7. PMC: 2782592. DOI: 10.1002/art.24658. View